Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547203 | 0.86 | ESR1 (0.65) | ESR1ESR2ACHESTAT3GRIA4 | |
| SCHEMBL29105134 | 0.83 | ESR1 (0.75) | ESR1ESR2 | |
| SCHEMBL8478139 | 0.82 | SLC6A2 (0.37) | ESR1ESR2ACHECHRNA7SMN1; SMN2 | |
| SCHEMBL68592 | 0.82 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL28468636 | 0.80 | IDO1 (0.38) | ACHEHCRTR2SMN1; SMN2IDO1ACACB | |
| SCHEMBL5313594 | 0.80 | ESR1 (0.53) | ESR1ESR2ACHESMN1; SMN2 | |
| SCHEMBL6546983 | 0.78 | ESR1 (0.57) | ESR1ESR2ACHESTAT3GRIA4 | |
| Ammonia Solution, Strong SCHEMBL5308343 | 0.78 | ESR1 (0.52) | ESR1ESR2ACHESMN1; SMN2 | |
| SCHEMBL28859481 | 0.78 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL6546854 | 0.78 | ESR1 (0.57) | ESR1ESR2ACHESTAT3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9061959-B2 | Method for manufacturing optically active menthol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9000192-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2646150-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | Takasago International Corporation (JP) | 2013-10-09 | — | — | EP | disclosed |
| EP-2647616-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | Takasago International Corporation (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130253228-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-26 | — | — | US | disclosed |
| US-20130217895-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2118101-B1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| WO-2012074128-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-06-07 | — | — | WO | disclosed |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2457655-A2 | Catalyst for asymmetric hydrogenation comprising peptides and method for manufacturing optically active carbonyl compound using the same | Takasago International Corporation (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| EP-2118101-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008110523-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | ESR1 3228/4885ESR2 2246/4885ACHE 83/4885 |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, HIRA, HRH1 | ESR1 3369/4885ESR2 2524/4885ACHE 133/4885 |
| US-20130217895-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, NQO1, CBR3 | ESR1 3401/4885ESR2 2813/4885ACHE 159/4885 |
| US-20130253228-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | MSMO1, GGPS1, MAN1B1 | ESR1 2083/4885ESR2 2021/4885ACHE 44/4885 |
| US-20080234313-A1 | NOVEL INHIBITORS | SF3A1, HBS1L, SF3A3 | ESR1 2279/4885ESR2 3343/4885ACHE 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.